David Williams
Concepts (525)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enzyme Inhibitors | 5 | 2023 | 372 | 0.790 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2023 | 14 | 0.630 |
Why?
| | Hypophosphatasia | 1 | 2018 | 8 | 0.610 |
Why?
| | Genetic Engineering | 1 | 2018 | 23 | 0.610 |
Why?
| | Alkaline Phosphatase | 1 | 2018 | 94 | 0.590 |
Why?
| | Disease Models, Animal | 5 | 2019 | 1478 | 0.590 |
Why?
| | Phenylenediamines | 1 | 2018 | 5 | 0.580 |
Why?
| | Cerebrovascular Circulation | 3 | 2016 | 128 | 0.540 |
Why?
| | Proto-Oncogene Proteins c-met | 5 | 2010 | 19 | 0.520 |
Why?
| | Retroviridae Infections | 2 | 2013 | 2 | 0.520 |
Why?
| | Personnel, Hospital | 2 | 2006 | 20 | 0.500 |
Why?
| | Tinnitus | 2 | 2017 | 60 | 0.500 |
Why?
| | Transcranial Magnetic Stimulation | 2 | 2017 | 72 | 0.490 |
Why?
| | Aminopyridines | 3 | 2010 | 15 | 0.480 |
Why?
| | Suction | 2 | 2013 | 24 | 0.460 |
Why?
| | Amines | 2 | 2014 | 38 | 0.440 |
Why?
| | Methamphetamine | 5 | 2014 | 198 | 0.430 |
Why?
| | Female | 48 | 2024 | 28171 | 0.430 |
Why?
| | Macaca mulatta | 2 | 2013 | 92 | 0.430 |
Why?
| | Humans | 61 | 2024 | 52483 | 0.410 |
Why?
| | Xenotropic murine leukemia virus-related virus | 1 | 2012 | 1 | 0.410 |
Why?
| | Antibodies, Monoclonal | 5 | 2014 | 481 | 0.390 |
Why?
| | Wounds and Injuries | 2 | 2006 | 309 | 0.390 |
Why?
| | Rural Health Services | 2 | 2013 | 170 | 0.380 |
Why?
| | Heart Rate | 5 | 2019 | 318 | 0.380 |
Why?
| | Structure-Activity Relationship | 11 | 2023 | 404 | 0.380 |
Why?
| | Male | 43 | 2024 | 26761 | 0.370 |
Why?
| | Caregivers | 3 | 2019 | 240 | 0.370 |
Why?
| | Protein Kinase Inhibitors | 3 | 2010 | 227 | 0.360 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 2011 | 19 | 0.350 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2011 | 48 | 0.350 |
Why?
| | Obesity | 6 | 2024 | 1162 | 0.350 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 267 | 0.340 |
Why?
| | Depressive Disorder | 2 | 2010 | 334 | 0.340 |
Why?
| | United States Department of Veterans Affairs | 3 | 2021 | 293 | 0.340 |
Why?
| | Antineoplastic Agents | 5 | 2010 | 1222 | 0.330 |
Why?
| | Telemedicine | 3 | 2013 | 494 | 0.330 |
Why?
| | Intubation, Intratracheal | 1 | 2011 | 122 | 0.320 |
Why?
| | Animals | 29 | 2021 | 13505 | 0.320 |
Why?
| | Respiration, Artificial | 2 | 2016 | 308 | 0.320 |
Why?
| | Breast Feeding | 2 | 2022 | 197 | 0.320 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2020 | 58 | 0.310 |
Why?
| | Time Factors | 10 | 2020 | 2968 | 0.300 |
Why?
| | Dietary Supplements | 3 | 2018 | 465 | 0.300 |
Why?
| | Insulin Resistance | 2 | 2020 | 275 | 0.280 |
Why?
| | Blood Pressure | 4 | 2016 | 537 | 0.280 |
Why?
| | Gait Disorders, Neurologic | 2 | 2018 | 37 | 0.280 |
Why?
| | Leptin | 2 | 2022 | 148 | 0.270 |
Why?
| | Dietary Proteins | 2 | 2020 | 252 | 0.270 |
Why?
| | Infant, Newborn | 9 | 2021 | 2867 | 0.270 |
Why?
| | Brain | 5 | 2021 | 1323 | 0.260 |
Why?
| | Parkinson Disease | 2 | 2018 | 155 | 0.250 |
Why?
| | Accidents, Occupational | 1 | 2006 | 20 | 0.250 |
Why?
| | Infant, Premature | 5 | 2016 | 333 | 0.240 |
Why?
| | Cerebral Hemorrhage | 2 | 2016 | 97 | 0.230 |
Why?
| | Adiposity | 2 | 2024 | 143 | 0.230 |
Why?
| | Occupational Diseases | 1 | 2006 | 85 | 0.230 |
Why?
| | Pregnancy | 11 | 2024 | 2680 | 0.220 |
Why?
| | Cross-Over Studies | 7 | 2017 | 238 | 0.220 |
Why?
| | Infant, Premature, Diseases | 2 | 2016 | 94 | 0.210 |
Why?
| | Veterans | 2 | 2021 | 583 | 0.210 |
Why?
| | Depression | 3 | 2014 | 600 | 0.210 |
Why?
| | Rats, Sprague-Dawley | 12 | 2014 | 1563 | 0.210 |
Why?
| | Insulin | 3 | 2022 | 479 | 0.210 |
Why?
| | Ethers | 1 | 2023 | 8 | 0.210 |
Why?
| | Internship and Residency | 2 | 2019 | 448 | 0.210 |
Why?
| | Executive Function | 2 | 2021 | 72 | 0.210 |
Why?
| | Pyrroles | 3 | 2008 | 71 | 0.200 |
Why?
| | Sertraline | 2 | 2014 | 44 | 0.200 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 403 | 0.200 |
Why?
| | Students, Medical | 2 | 2017 | 159 | 0.190 |
Why?
| | Adult | 17 | 2019 | 14161 | 0.190 |
Why?
| | Maternal-Fetal Exchange | 2 | 2020 | 49 | 0.190 |
Why?
| | Liver Failure, Acute | 1 | 2022 | 56 | 0.190 |
Why?
| | Pedunculopontine Tegmental Nucleus | 2 | 2012 | 24 | 0.190 |
Why?
| | HeLa Cells | 2 | 2023 | 265 | 0.180 |
Why?
| | End Stage Liver Disease | 1 | 2022 | 48 | 0.180 |
Why?
| | Body Composition | 2 | 2020 | 338 | 0.180 |
Why?
| | Energy Metabolism | 2 | 2021 | 302 | 0.180 |
Why?
| | Phencyclidine | 2 | 2011 | 33 | 0.180 |
Why?
| | Myocardium | 2 | 2021 | 453 | 0.180 |
Why?
| | Middle Aged | 12 | 2019 | 13028 | 0.180 |
Why?
| | Evoked Potentials | 1 | 2021 | 67 | 0.180 |
Why?
| | Olivary Nucleus | 2 | 2011 | 6 | 0.180 |
Why?
| | Myoglobin | 1 | 2021 | 25 | 0.180 |
Why?
| | Purkinje Cells | 2 | 2011 | 15 | 0.180 |
Why?
| | Cocaine-Related Disorders | 2 | 2014 | 207 | 0.170 |
Why?
| | Mice | 13 | 2021 | 5949 | 0.170 |
Why?
| | Infant Food | 1 | 2020 | 28 | 0.170 |
Why?
| | Growth | 1 | 2020 | 40 | 0.170 |
Why?
| | Bottle Feeding | 1 | 2020 | 34 | 0.170 |
Why?
| | Spumavirus | 1 | 2020 | 1 | 0.170 |
Why?
| | Body Temperature Regulation | 1 | 2020 | 30 | 0.170 |
Why?
| | Microsomes, Liver | 3 | 2018 | 184 | 0.170 |
Why?
| | Rats | 12 | 2014 | 3220 | 0.170 |
Why?
| | Neurons | 3 | 2012 | 418 | 0.170 |
Why?
| | Acetaminophen | 2 | 2022 | 279 | 0.170 |
Why?
| | Blood Glucose | 2 | 2020 | 473 | 0.170 |
Why?
| | Brain Concussion | 1 | 2021 | 109 | 0.170 |
Why?
| | Genome, Viral | 1 | 2020 | 83 | 0.160 |
Why?
| | Concept Formation | 1 | 2019 | 12 | 0.160 |
Why?
| | Energy Intake | 1 | 2020 | 174 | 0.160 |
Why?
| | Eating | 1 | 2020 | 159 | 0.160 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2019 | 11 | 0.160 |
Why?
| | Phenotype | 2 | 2021 | 789 | 0.160 |
Why?
| | Temperature | 1 | 2020 | 183 | 0.160 |
Why?
| | Case-Control Studies | 4 | 2019 | 1201 | 0.160 |
Why?
| | Athletic Injuries | 1 | 2021 | 192 | 0.160 |
Why?
| | Diastole | 2 | 2016 | 70 | 0.160 |
Why?
| | Patient Care Team | 3 | 2013 | 272 | 0.160 |
Why?
| | Middle Cerebral Artery | 2 | 2016 | 33 | 0.150 |
Why?
| | Diabetes, Gestational | 1 | 2019 | 53 | 0.150 |
Why?
| | Freezing Reaction, Cataleptic | 1 | 2018 | 5 | 0.150 |
Why?
| | Virus Replication | 1 | 2020 | 150 | 0.150 |
Why?
| | Feedback | 1 | 2019 | 52 | 0.150 |
Why?
| | Colorectal Surgery | 1 | 2018 | 16 | 0.150 |
Why?
| | Sheep | 1 | 2018 | 96 | 0.150 |
Why?
| | Point Mutation | 1 | 2018 | 67 | 0.150 |
Why?
| | Crystallography, X-Ray | 5 | 2010 | 156 | 0.150 |
Why?
| | Pyridones | 2 | 2009 | 36 | 0.150 |
Why?
| | Receptors, Growth Factor | 2 | 2008 | 7 | 0.150 |
Why?
| | Cannabidiol | 1 | 2019 | 43 | 0.150 |
Why?
| | Arkansas | 6 | 2019 | 2028 | 0.150 |
Why?
| | Burnout, Professional | 1 | 2019 | 55 | 0.150 |
Why?
| | Treatment Outcome | 7 | 2017 | 5422 | 0.150 |
Why?
| | Cell Line, Tumor | 7 | 2017 | 1470 | 0.150 |
Why?
| | Certification | 1 | 2018 | 51 | 0.150 |
Why?
| | Bone Development | 1 | 2018 | 66 | 0.150 |
Why?
| | Body Mass Index | 4 | 2024 | 689 | 0.150 |
Why?
| | Mental Health Services | 1 | 2021 | 212 | 0.150 |
Why?
| | Military Personnel | 2 | 2019 | 177 | 0.150 |
Why?
| | Blood Flow Velocity | 3 | 2016 | 95 | 0.140 |
Why?
| | Child | 8 | 2024 | 7248 | 0.140 |
Why?
| | Foot | 1 | 2018 | 41 | 0.140 |
Why?
| | Ethanol | 2 | 2011 | 342 | 0.140 |
Why?
| | Action Potentials | 3 | 2012 | 120 | 0.140 |
Why?
| | Walking | 1 | 2018 | 104 | 0.140 |
Why?
| | Cognition | 1 | 2020 | 331 | 0.140 |
Why?
| | Psychiatry | 2 | 2017 | 100 | 0.140 |
Why?
| | United States | 7 | 2021 | 5192 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 2 | 2008 | 151 | 0.140 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2017 | 23 | 0.140 |
Why?
| | Cellular Microenvironment | 1 | 2017 | 30 | 0.130 |
Why?
| | Platelet Activation | 1 | 2017 | 47 | 0.130 |
Why?
| | Electroacupuncture | 1 | 2016 | 2 | 0.130 |
Why?
| | Risk Factors | 6 | 2019 | 3889 | 0.130 |
Why?
| | Pilot Projects | 3 | 2017 | 721 | 0.130 |
Why?
| | Epinephrine | 1 | 2017 | 97 | 0.130 |
Why?
| | Substance-Related Disorders | 2 | 2014 | 609 | 0.130 |
Why?
| | Combat Disorders | 1 | 2016 | 37 | 0.130 |
Why?
| | Blood Specimen Collection | 1 | 2016 | 35 | 0.130 |
Why?
| | Pain | 2 | 2016 | 362 | 0.130 |
Why?
| | Attention | 1 | 2017 | 168 | 0.130 |
Why?
| | Perception | 1 | 2017 | 120 | 0.130 |
Why?
| | Citrus paradisi | 2 | 2008 | 10 | 0.130 |
Why?
| | Food-Drug Interactions | 2 | 2008 | 14 | 0.130 |
Why?
| | Neonatal Screening | 1 | 2016 | 49 | 0.130 |
Why?
| | Temporal Lobe | 2 | 2017 | 70 | 0.130 |
Why?
| | Cell Membrane | 1 | 2017 | 245 | 0.130 |
Why?
| | Serotonin | 1 | 2017 | 146 | 0.130 |
Why?
| | Career Choice | 1 | 2017 | 116 | 0.130 |
Why?
| | Itraconazole | 2 | 2008 | 38 | 0.130 |
Why?
| | Cerebral Ventricles | 1 | 2016 | 23 | 0.130 |
Why?
| | Melatonin | 1 | 2015 | 17 | 0.120 |
Why?
| | Quality of Life | 2 | 2019 | 879 | 0.120 |
Why?
| | Arterial Pressure | 1 | 2016 | 45 | 0.120 |
Why?
| | Antibodies, Viral | 2 | 2013 | 109 | 0.120 |
Why?
| | Physicians | 1 | 2019 | 241 | 0.120 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 804 | 0.120 |
Why?
| | Bone Neoplasms | 1 | 2017 | 184 | 0.120 |
Why?
| | Cholinergic Agonists | 2 | 2011 | 10 | 0.120 |
Why?
| | Quality-Adjusted Life Years | 2 | 2015 | 66 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2010 | 220 | 0.110 |
Why?
| | Blood Platelets | 1 | 2017 | 259 | 0.110 |
Why?
| | Signal Transduction | 2 | 2022 | 1671 | 0.110 |
Why?
| | Excitatory Amino Acid Agonists | 2 | 2011 | 16 | 0.110 |
Why?
| | Amphetamine | 1 | 2014 | 38 | 0.110 |
Why?
| | Cell Differentiation | 1 | 2017 | 665 | 0.110 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2014 | 18 | 0.110 |
Why?
| | Massage | 1 | 2014 | 6 | 0.110 |
Why?
| | Autistic Disorder | 1 | 2015 | 126 | 0.110 |
Why?
| | Osteoclasts | 1 | 2017 | 428 | 0.110 |
Why?
| | Drinking | 2 | 2020 | 43 | 0.110 |
Why?
| | Severity of Illness Index | 4 | 2022 | 1026 | 0.110 |
Why?
| | Behavior Therapy | 1 | 2015 | 179 | 0.110 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2014 | 62 | 0.110 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 47 | 0.110 |
Why?
| | Simian foamy virus | 1 | 2013 | 1 | 0.110 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2013 | 3 | 0.110 |
Why?
| | Smoking | 1 | 2017 | 520 | 0.100 |
Why?
| | Antifungal Agents | 2 | 2008 | 347 | 0.100 |
Why?
| | Aged | 6 | 2021 | 10121 | 0.100 |
Why?
| | Double-Blind Method | 4 | 2017 | 713 | 0.100 |
Why?
| | Binding Sites | 2 | 2014 | 377 | 0.100 |
Why?
| | Bacillus | 1 | 2012 | 4 | 0.100 |
Why?
| | Biophysical Phenomena | 1 | 2012 | 18 | 0.100 |
Why?
| | Drug Contamination | 1 | 2012 | 4 | 0.100 |
Why?
| | Nebulizers and Vaporizers | 1 | 2013 | 58 | 0.100 |
Why?
| | Kangaroo-Mother Care Method | 1 | 2013 | 8 | 0.100 |
Why?
| | Albuterol | 1 | 2013 | 57 | 0.100 |
Why?
| | Saliva | 1 | 2013 | 56 | 0.100 |
Why?
| | Models, Biological | 3 | 2019 | 735 | 0.100 |
Why?
| | Child, Preschool | 4 | 2024 | 4076 | 0.100 |
Why?
| | Cardiotonic Agents | 1 | 2013 | 82 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2013 | 77 | 0.100 |
Why?
| | Drug Overdose | 1 | 2014 | 163 | 0.100 |
Why?
| | Coculture Techniques | 1 | 2012 | 144 | 0.100 |
Why?
| | Primary Health Care | 3 | 2013 | 376 | 0.100 |
Why?
| | Hydrocortisone | 1 | 2013 | 111 | 0.100 |
Why?
| | Hypotension | 1 | 2013 | 62 | 0.100 |
Why?
| | Registries | 1 | 2015 | 581 | 0.100 |
Why?
| | DNA, Viral | 1 | 2012 | 137 | 0.100 |
Why?
| | Dopamine | 1 | 2013 | 173 | 0.100 |
Why?
| | Calcium Channels, N-Type | 1 | 2011 | 2 | 0.100 |
Why?
| | Anthropometry | 2 | 2024 | 101 | 0.100 |
Why?
| | Intralaminar Thalamic Nuclei | 1 | 2011 | 6 | 0.090 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 229 | 0.090 |
Why?
| | Functional Laterality | 1 | 2012 | 90 | 0.090 |
Why?
| | Fetal Death | 1 | 2011 | 24 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2019 | 1378 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 461 | 0.090 |
Why?
| | Stem Cell Transplantation | 1 | 2012 | 185 | 0.090 |
Why?
| | Cells, Cultured | 2 | 2012 | 1567 | 0.090 |
Why?
| | Blotting, Western | 1 | 2012 | 590 | 0.090 |
Why?
| | Patch-Clamp Techniques | 4 | 2012 | 111 | 0.090 |
Why?
| | Pain Management | 1 | 2013 | 178 | 0.090 |
Why?
| | Sleep, REM | 1 | 2011 | 44 | 0.090 |
Why?
| | Pons | 1 | 2011 | 33 | 0.090 |
Why?
| | Brain Waves | 1 | 2011 | 19 | 0.090 |
Why?
| | Echoencephalography | 1 | 2011 | 8 | 0.090 |
Why?
| | Nerve Fibers | 1 | 2011 | 12 | 0.090 |
Why?
| | Electrocardiography | 1 | 2012 | 268 | 0.090 |
Why?
| | Neurogenesis | 1 | 2011 | 27 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2013 | 273 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2021 | 747 | 0.090 |
Why?
| | Central Nervous System Depressants | 1 | 2011 | 80 | 0.090 |
Why?
| | Carbon Dioxide | 1 | 2011 | 97 | 0.090 |
Why?
| | Professional Role | 1 | 2011 | 78 | 0.080 |
Why?
| | Social Environment | 1 | 2011 | 81 | 0.080 |
Why?
| | Cerebellum | 1 | 2011 | 125 | 0.080 |
Why?
| | Synapses | 1 | 2010 | 74 | 0.080 |
Why?
| | Administration, Oral | 4 | 2018 | 451 | 0.080 |
Why?
| | Atrial Fibrillation | 1 | 2012 | 200 | 0.080 |
Why?
| | Linear Models | 3 | 2016 | 287 | 0.080 |
Why?
| | Teaching | 1 | 2011 | 115 | 0.080 |
Why?
| | Data Collection | 1 | 2011 | 290 | 0.080 |
Why?
| | Parents | 1 | 2013 | 335 | 0.080 |
Why?
| | Chronic Disease | 1 | 2012 | 586 | 0.080 |
Why?
| | Dihydropyridines | 1 | 2009 | 7 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 1678 | 0.080 |
Why?
| | Health Care Costs | 1 | 2010 | 174 | 0.080 |
Why?
| | Drug Design | 1 | 2010 | 120 | 0.080 |
Why?
| | Learning | 1 | 2011 | 160 | 0.080 |
Why?
| | Gestational Age | 3 | 2019 | 417 | 0.080 |
Why?
| | Phosphotransferases | 1 | 2008 | 17 | 0.070 |
Why?
| | Body Weight | 2 | 2021 | 523 | 0.070 |
Why?
| | Cooperative Behavior | 1 | 2010 | 227 | 0.070 |
Why?
| | Diet, High-Fat | 2 | 2021 | 236 | 0.070 |
Why?
| | Young Adult | 5 | 2017 | 4329 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 1546 | 0.070 |
Why?
| | Electroencephalography | 1 | 2010 | 312 | 0.070 |
Why?
| | Liver | 3 | 2019 | 1156 | 0.070 |
Why?
| | Mice, Inbred Strains | 2 | 2019 | 163 | 0.070 |
Why?
| | Urea | 1 | 2008 | 82 | 0.070 |
Why?
| | Beverages | 2 | 2008 | 57 | 0.070 |
Why?
| | Triazines | 1 | 2008 | 26 | 0.070 |
Why?
| | Logistic Models | 2 | 2012 | 925 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2017 | 1212 | 0.070 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2008 | 52 | 0.070 |
Why?
| | Stomach Neoplasms | 2 | 2008 | 194 | 0.070 |
Why?
| | Adolescent | 5 | 2021 | 6739 | 0.070 |
Why?
| | Swimming | 1 | 2006 | 22 | 0.070 |
Why?
| | Central Nervous System Stimulants | 1 | 2009 | 206 | 0.070 |
Why?
| | Bicycling | 1 | 2006 | 28 | 0.070 |
Why?
| | Glioma | 1 | 2007 | 78 | 0.070 |
Why?
| | Monitoring, Physiologic | 2 | 2019 | 122 | 0.070 |
Why?
| | Running | 1 | 2006 | 22 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2018 | 339 | 0.070 |
Why?
| | Motor Activity | 3 | 2014 | 223 | 0.060 |
Why?
| | Fetus | 3 | 2014 | 194 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 443 | 0.060 |
Why?
| | Receptors, Vasopressin | 1 | 2005 | 23 | 0.060 |
Why?
| | Prospective Studies | 3 | 2019 | 2481 | 0.060 |
Why?
| | Multiple Myeloma | 2 | 2012 | 3049 | 0.060 |
Why?
| | Cell Survival | 3 | 2017 | 612 | 0.060 |
Why?
| | Dogs | 2 | 2020 | 180 | 0.060 |
Why?
| | Alkyl and Aryl Transferases | 1 | 2005 | 4 | 0.060 |
Why?
| | Poliomyelitis | 1 | 2005 | 5 | 0.060 |
Why?
| | Ambulatory Care | 2 | 2021 | 239 | 0.060 |
Why?
| | Benzodiazepines | 1 | 2005 | 71 | 0.060 |
Why?
| | Ambulatory Care Facilities | 2 | 2021 | 124 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 1884 | 0.060 |
Why?
| | Spheroids, Cellular | 1 | 2005 | 27 | 0.060 |
Why?
| | Quinolines | 1 | 2005 | 44 | 0.060 |
Why?
| | Area Under Curve | 3 | 2014 | 180 | 0.060 |
Why?
| | Kinetics | 2 | 2020 | 626 | 0.060 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2004 | 26 | 0.060 |
Why?
| | beta-Cyclodextrins | 1 | 2004 | 17 | 0.060 |
Why?
| | Thiazoles | 1 | 2004 | 55 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 944 | 0.050 |
Why?
| | Brain Neoplasms | 1 | 2007 | 291 | 0.050 |
Why?
| | Protein Binding | 3 | 2014 | 667 | 0.050 |
Why?
| | Placebos | 2 | 2014 | 85 | 0.050 |
Why?
| | Louisiana | 2 | 2019 | 41 | 0.050 |
Why?
| | Insurance, Psychiatric | 1 | 2003 | 3 | 0.050 |
Why?
| | Insurance Benefits | 1 | 2003 | 7 | 0.050 |
Why?
| | Cell Proliferation | 4 | 2008 | 1023 | 0.050 |
Why?
| | Odds Ratio | 2 | 2016 | 558 | 0.050 |
Why?
| | Health Services | 1 | 2003 | 65 | 0.050 |
Why?
| | Community Mental Health Services | 1 | 2003 | 46 | 0.050 |
Why?
| | Palmitates | 1 | 2022 | 29 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2017 | 146 | 0.050 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2022 | 71 | 0.050 |
Why?
| | Clinical Competence | 2 | 2018 | 406 | 0.050 |
Why?
| | Sex Factors | 2 | 2019 | 727 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2019 | 1229 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 192 | 0.050 |
Why?
| | Physical Therapy Modalities | 1 | 2021 | 38 | 0.050 |
Why?
| | Medically Uninsured | 1 | 2021 | 46 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2021 | 60 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2013 | 323 | 0.040 |
Why?
| | Carbachol | 2 | 2011 | 26 | 0.040 |
Why?
| | Postural Balance | 1 | 2021 | 58 | 0.040 |
Why?
| | Sodium Channel Blockers | 2 | 2011 | 14 | 0.040 |
Why?
| | Athletes | 1 | 2021 | 104 | 0.040 |
Why?
| | Weight Gain | 1 | 2022 | 240 | 0.040 |
Why?
| | Membrane Potentials | 2 | 2011 | 109 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2013 | 554 | 0.040 |
Why?
| | Veterans Health | 1 | 2021 | 63 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 70 | 0.040 |
Why?
| | Diet, Fat-Restricted | 1 | 2020 | 13 | 0.040 |
Why?
| | Mice, Obese | 1 | 2020 | 22 | 0.040 |
Why?
| | Fatty Acids | 1 | 2021 | 149 | 0.040 |
Why?
| | Body Fat Distribution | 1 | 2020 | 10 | 0.040 |
Why?
| | Animals, Newborn | 2 | 2012 | 362 | 0.040 |
Why?
| | Reaction Time | 1 | 2021 | 209 | 0.040 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2020 | 5 | 0.040 |
Why?
| | Macaca | 1 | 2020 | 9 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2021 | 187 | 0.040 |
Why?
| | Adipose Tissue, Brown | 1 | 2020 | 44 | 0.040 |
Why?
| | Absorptiometry, Photon | 1 | 2020 | 162 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2021 | 326 | 0.040 |
Why?
| | Alcoholism | 1 | 2003 | 239 | 0.040 |
Why?
| | Memory | 1 | 2020 | 100 | 0.040 |
Why?
| | Neuroimaging | 1 | 2020 | 94 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2021 | 198 | 0.040 |
Why?
| | Patient Compliance | 2 | 2014 | 230 | 0.040 |
Why?
| | Family Relations | 1 | 2019 | 23 | 0.040 |
Why?
| | Proteomics | 1 | 2022 | 329 | 0.040 |
Why?
| | Exercise | 1 | 2024 | 547 | 0.040 |
Why?
| | Language | 1 | 2020 | 138 | 0.040 |
Why?
| | Cohort Studies | 2 | 2016 | 1542 | 0.040 |
Why?
| | Phylogeny | 1 | 2020 | 231 | 0.040 |
Why?
| | Drug Synergism | 1 | 2019 | 150 | 0.040 |
Why?
| | Students | 1 | 2021 | 228 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2020 | 338 | 0.040 |
Why?
| | Specialty Boards | 1 | 2018 | 24 | 0.040 |
Why?
| | Mothers | 1 | 2021 | 270 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 182 | 0.040 |
Why?
| | Interpersonal Relations | 1 | 2019 | 106 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2012 | 6607 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2021 | 879 | 0.040 |
Why?
| | Animals, Outbred Strains | 1 | 2017 | 12 | 0.040 |
Why?
| | Social Support | 1 | 2019 | 268 | 0.030 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.030 |
Why?
| | Transglutaminases | 1 | 2017 | 14 | 0.030 |
Why?
| | Parietal Lobe | 1 | 2017 | 26 | 0.030 |
Why?
| | Cell Line | 1 | 2020 | 1030 | 0.030 |
Why?
| | Toxicity Tests | 1 | 2017 | 57 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 64 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2019 | 230 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2017 | 72 | 0.030 |
Why?
| | Organ Size | 1 | 2017 | 228 | 0.030 |
Why?
| | Polysaccharides | 1 | 2017 | 57 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 522 | 0.030 |
Why?
| | Educational Measurement | 1 | 2018 | 196 | 0.030 |
Why?
| | Plant Extracts | 1 | 2019 | 194 | 0.030 |
Why?
| | Medicine | 1 | 2017 | 54 | 0.030 |
Why?
| | Prefrontal Cortex | 1 | 2017 | 85 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 192 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 219 | 0.030 |
Why?
| | Accidental Falls | 1 | 2018 | 105 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2017 | 126 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 2099 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 180 | 0.030 |
Why?
| | Mice, Nude | 2 | 2009 | 265 | 0.030 |
Why?
| | Cannabis | 1 | 2019 | 150 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2017 | 110 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 2 | 2008 | 74 | 0.030 |
Why?
| | Models, Molecular | 2 | 2009 | 348 | 0.030 |
Why?
| | Umbilical Arteries | 1 | 2016 | 23 | 0.030 |
Why?
| | Pharmaceutical Solutions | 2 | 2008 | 9 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 243 | 0.030 |
Why?
| | Autonomic Nervous System | 1 | 2016 | 60 | 0.030 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2016 | 20 | 0.030 |
Why?
| | Apgar Score | 1 | 2016 | 35 | 0.030 |
Why?
| | Molecular Structure | 2 | 2008 | 314 | 0.030 |
Why?
| | Infant, Extremely Premature | 1 | 2016 | 33 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2017 | 251 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 1006 | 0.030 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2017 | 181 | 0.030 |
Why?
| | Up-Regulation | 1 | 2017 | 454 | 0.030 |
Why?
| | Calcium | 1 | 2017 | 376 | 0.030 |
Why?
| | Echocardiography | 1 | 2018 | 415 | 0.030 |
Why?
| | Cost of Illness | 1 | 2015 | 121 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 2014 | 15 | 0.030 |
Why?
| | GABA Agonists | 1 | 2014 | 13 | 0.030 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2014 | 41 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 591 | 0.030 |
Why?
| | Locomotion | 1 | 2014 | 85 | 0.030 |
Why?
| | Half-Life | 1 | 2014 | 88 | 0.030 |
Why?
| | Amphetamine-Related Disorders | 1 | 2014 | 93 | 0.030 |
Why?
| | Particle Size | 1 | 2013 | 82 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2013 | 33 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1105 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2013 | 120 | 0.030 |
Why?
| | MicroRNAs | 1 | 2017 | 387 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 41 | 0.030 |
Why?
| | Aerosols | 1 | 2013 | 75 | 0.030 |
Why?
| | Biophysics | 1 | 2012 | 15 | 0.030 |
Why?
| | Nasal Cavity | 1 | 2013 | 7 | 0.030 |
Why?
| | Plasma | 1 | 2013 | 45 | 0.030 |
Why?
| | Viral Load | 1 | 2013 | 82 | 0.030 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2013 | 30 | 0.030 |
Why?
| | Ion Channel Gating | 1 | 2012 | 33 | 0.030 |
Why?
| | Theophylline | 1 | 2012 | 17 | 0.030 |
Why?
| | Touch | 1 | 2013 | 24 | 0.030 |
Why?
| | Infant Behavior | 1 | 2013 | 18 | 0.030 |
Why?
| | Medically Underserved Area | 1 | 2013 | 46 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 2012 | 34 | 0.030 |
Why?
| | Electric Stimulation | 1 | 2012 | 107 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 395 | 0.030 |
Why?
| | Remission Induction | 1 | 2013 | 218 | 0.020 |
Why?
| | Medication Adherence | 1 | 2014 | 133 | 0.020 |
Why?
| | Equipment Design | 1 | 2013 | 293 | 0.020 |
Why?
| | Systole | 1 | 2012 | 72 | 0.020 |
Why?
| | Sleep | 1 | 2014 | 187 | 0.020 |
Why?
| | Caffeine | 1 | 2012 | 61 | 0.020 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2014 | 135 | 0.020 |
Why?
| | Ion Channels | 1 | 2012 | 70 | 0.020 |
Why?
| | Heart Atria | 1 | 2012 | 63 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 672 | 0.020 |
Why?
| | Psychotherapy | 1 | 2013 | 113 | 0.020 |
Why?
| | omega-Agatoxin IVA | 1 | 2011 | 1 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 639 | 0.020 |
Why?
| | Infant | 1 | 2020 | 3733 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2013 | 177 | 0.020 |
Why?
| | Oscillometry | 1 | 2011 | 9 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 60 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 673 | 0.020 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2012 | 108 | 0.020 |
Why?
| | Sodium Channels | 1 | 2011 | 11 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2011 | 84 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 2013 | 154 | 0.020 |
Why?
| | Acculturation | 1 | 2011 | 21 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2011 | 53 | 0.020 |
Why?
| | Social Identification | 1 | 2011 | 20 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 111 | 0.020 |
Why?
| | Femoral Artery | 1 | 2011 | 103 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2011 | 86 | 0.020 |
Why?
| | Clinical Clerkship | 1 | 2011 | 29 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 87 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 430 | 0.020 |
Why?
| | Vesicular Glutamate Transport Protein 2 | 1 | 2010 | 6 | 0.020 |
Why?
| | Cerebellar Cortex | 1 | 2010 | 5 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2012 | 488 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2010 | 10 | 0.020 |
Why?
| | N-Methylaspartate | 1 | 2010 | 18 | 0.020 |
Why?
| | Electrophysiological Phenomena | 1 | 2010 | 19 | 0.020 |
Why?
| | Theta Rhythm | 1 | 2010 | 9 | 0.020 |
Why?
| | Muscarinic Agonists | 1 | 2010 | 11 | 0.020 |
Why?
| | Potassium Channel Blockers | 1 | 2010 | 16 | 0.020 |
Why?
| | Schools, Medical | 1 | 2011 | 69 | 0.020 |
Why?
| | Kainic Acid | 1 | 2010 | 24 | 0.020 |
Why?
| | Potassium Channels | 1 | 2010 | 32 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 483 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2012 | 220 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 871 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 149 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 2011 | 250 | 0.020 |
Why?
| | Stereotyped Behavior | 1 | 2009 | 17 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 1132 | 0.020 |
Why?
| | Dextroamphetamine | 1 | 2009 | 39 | 0.020 |
Why?
| | Incidence | 1 | 2012 | 1062 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2011 | 253 | 0.020 |
Why?
| | Fetal Development | 1 | 2009 | 50 | 0.020 |
Why?
| | Blood Proteins | 1 | 2009 | 85 | 0.020 |
Why?
| | Solubility | 1 | 2009 | 79 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 220 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 30 | 0.020 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2008 | 20 | 0.020 |
Why?
| | Ether-A-Go-Go Potassium Channels | 1 | 2008 | 5 | 0.020 |
Why?
| | Caco-2 Cells | 1 | 2008 | 31 | 0.020 |
Why?
| | Risk Assessment | 1 | 2012 | 1327 | 0.020 |
Why?
| | Kidney | 1 | 2012 | 707 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2008 | 312 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2008 | 78 | 0.020 |
Why?
| | Protein Conformation | 1 | 2008 | 176 | 0.020 |
Why?
| | Glutathione Transferase | 1 | 2008 | 174 | 0.020 |
Why?
| | Hypertension | 1 | 2012 | 565 | 0.020 |
Why?
| | Exercise Tolerance | 1 | 2006 | 46 | 0.020 |
Why?
| | Physical Endurance | 1 | 2006 | 34 | 0.020 |
Why?
| | Hepatocytes | 1 | 2008 | 190 | 0.020 |
Why?
| | Computer Simulation | 1 | 2007 | 290 | 0.020 |
Why?
| | Respiration | 1 | 2006 | 101 | 0.020 |
Why?
| | Benzazepines | 1 | 2005 | 20 | 0.020 |
Why?
| | Molecular Weight | 1 | 2005 | 82 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2006 | 198 | 0.020 |
Why?
| | Farnesyltranstransferase | 1 | 2005 | 4 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2006 | 253 | 0.010 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2005 | 136 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 595 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2005 | 460 | 0.010 |
Why?
| | Cyclodextrins | 1 | 2004 | 18 | 0.010 |
Why?
| | Biological Availability | 1 | 2004 | 108 | 0.010 |
Why?
| | Leukemia | 1 | 2004 | 67 | 0.010 |
Why?
| | Neoplasms, Experimental | 1 | 2004 | 114 | 0.010 |
Why?
| | Gatekeeping | 1 | 2003 | 9 | 0.010 |
Why?
| | Cost Control | 1 | 2003 | 13 | 0.010 |
Why?
| | Tennessee | 1 | 2003 | 37 | 0.010 |
Why?
| | Cost Sharing | 1 | 2003 | 16 | 0.010 |
Why?
| | Georgia | 1 | 2003 | 42 | 0.010 |
Why?
| | Alabama | 1 | 2003 | 67 | 0.010 |
Why?
| | Mississippi | 1 | 2003 | 90 | 0.010 |
Why?
| | Health Policy | 1 | 2003 | 158 | 0.010 |
Why?
|
|
Williams's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|